Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07439887 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
A Phase 1 study of Stargardt Disease, sponsored by Ray Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT07439887 is a Phase 1 study of Stargardt Disease that is actively recruiting participants, run by Ray Therapeutics. The registered enrollment target is 18 participants, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07439887, a Phase 1 study of Stargardt Disease, is actively recruiting participants, sponsored by Ray Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years.
Conditions Studied
Interventions
- GENETIC RTx-021
Study Locations (2)
California
- RayTx Clinical Site - Bakersfield
Texas
- RayTx Clinical Site - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07439887
The ClinicalTrials.gov registry entry for NCT07439887 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (80% lower). The listed sponsor is Ray Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which RTx-021 is the first listed.
NCT07439887 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT07439887 about?
NCT07439887 is a clinical study titled "Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease". A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in...
What is the current status of trial NCT07439887?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-01-28. Estimated completion is 2030-12-01.
What conditions does trial NCT07439887 study?
This clinical trial studies the following conditions: Stargardt Disease.
What interventions are being tested in trial NCT07439887?
The interventions under investigation include: RTx-021 (GENETIC).
Who is sponsoring clinical trial NCT07439887?
This trial is sponsored by Ray Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07439887 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
Oral Metformin for Treatment of ABCA4 Retinopathy
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
RECRUITING · Phase 1
-
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.